Abstract
In this Practice Point commentary, I describe the findings and limitations of a 52-week, open-label, noninferiority, head-to-head comparison study of the basal insulin analogs detemir and glargine. Rosenstock et al. enrolled 582 insulin-näve individuals with type 2 diabetes mellitus inadequately controlled with oral antidiabetic agents. Participants were randomly allocated to receive either detemir or glargine, titrated to a target fasting plasma glucose level ≤6 mmol/l in the absence of hypoglycemia. Detemir was administered once-daily or (if needed) twice-daily to control predinner blood glucose levels, whereas glargine was administered only once-daily. Comparable improvements in glycemic control were observed in the two treatment groups. By contrast, less weight gain occurred with detemir than with glargine. Nonetheless, higher levels of detemir than glargine were required to achieve these beneficial effects and only 45% of patients in the detemir group remained on the once-daily dosing schedule. The implications of these observations for clinical practice are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 490-491 |
| Number of pages | 2 |
| Journal | Nature Clinical Practice Endocrinology and Metabolism |
| Volume | 4 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2008 |
Fingerprint
Keywords
- Basal insulin
- Detemir
- Glargine
- Glycemic control
- Type 2 diabetes mellitus
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
How do detemir and glargine compare when added to oral agents in insulin-näve patients with type 2 diabetes mellitus? / Marks, Jennifer B.
In: Nature Clinical Practice Endocrinology and Metabolism, Vol. 4, No. 9, 01.09.2008, p. 490-491.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - How do detemir and glargine compare when added to oral agents in insulin-näve patients with type 2 diabetes mellitus?
AU - Marks, Jennifer B
PY - 2008/9/1
Y1 - 2008/9/1
N2 - In this Practice Point commentary, I describe the findings and limitations of a 52-week, open-label, noninferiority, head-to-head comparison study of the basal insulin analogs detemir and glargine. Rosenstock et al. enrolled 582 insulin-näve individuals with type 2 diabetes mellitus inadequately controlled with oral antidiabetic agents. Participants were randomly allocated to receive either detemir or glargine, titrated to a target fasting plasma glucose level ≤6 mmol/l in the absence of hypoglycemia. Detemir was administered once-daily or (if needed) twice-daily to control predinner blood glucose levels, whereas glargine was administered only once-daily. Comparable improvements in glycemic control were observed in the two treatment groups. By contrast, less weight gain occurred with detemir than with glargine. Nonetheless, higher levels of detemir than glargine were required to achieve these beneficial effects and only 45% of patients in the detemir group remained on the once-daily dosing schedule. The implications of these observations for clinical practice are discussed.
AB - In this Practice Point commentary, I describe the findings and limitations of a 52-week, open-label, noninferiority, head-to-head comparison study of the basal insulin analogs detemir and glargine. Rosenstock et al. enrolled 582 insulin-näve individuals with type 2 diabetes mellitus inadequately controlled with oral antidiabetic agents. Participants were randomly allocated to receive either detemir or glargine, titrated to a target fasting plasma glucose level ≤6 mmol/l in the absence of hypoglycemia. Detemir was administered once-daily or (if needed) twice-daily to control predinner blood glucose levels, whereas glargine was administered only once-daily. Comparable improvements in glycemic control were observed in the two treatment groups. By contrast, less weight gain occurred with detemir than with glargine. Nonetheless, higher levels of detemir than glargine were required to achieve these beneficial effects and only 45% of patients in the detemir group remained on the once-daily dosing schedule. The implications of these observations for clinical practice are discussed.
KW - Basal insulin
KW - Detemir
KW - Glargine
KW - Glycemic control
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=50049114676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50049114676&partnerID=8YFLogxK
U2 - 10.1038/ncpendmet0900
DO - 10.1038/ncpendmet0900
M3 - Article
C2 - 18594486
AN - SCOPUS:50049114676
VL - 4
SP - 490
EP - 491
JO - Nature Reviews Endocrinology
JF - Nature Reviews Endocrinology
SN - 1759-5029
IS - 9
ER -